ROCHESTER, Minn. — A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL). Findings are published in the journal Blood.
Recent Posts
- Podcast – SENESCENT CELLS – An Important Target for Diseases of Aging
- Q&A: The Future of Space Medicine Research
- Trump administration halts use of human fetal tissue in NIH-funded research
- Bone cancer therapy unexpectedly makes tumours less painful
- Scientists solve a major roadblock holding back cancer cell therapy
- The Potential of Stem Cells to Improve Stroke Treatment
